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ABSTRACT 
BACKGROUND: Whether the association of height with cancers differ by insulin-like 
growth factors has not been fully elucidated. Therefore, this study aimed to investigate 
the sex-specific associations between height and 24 site-specific cancers to assess 
whether the association differed by IGF-1. 
METHODS: 414 923 participants from the UK Biobank prospective cohort study were 
included. The association of height (per 5 cm increment) with incidence and mortality 
from 24 cancer sites was investigated by using Cox proportional hazards models.   
RESULTS: The median follow-up was 6.0 years. In men, height was positively associated 
with incidence risk of all-cause cancer and at five sites (lung, lymphatic, leukaemia, non-
Hodgkin lymphoma and melanoma). In women, it was associated with breast, melanoma, 
lymphatic, non-Hodgkin lymphomas and all-cause cancer. The association was stronger 
in women than men for all-cause cancer incidence. The strength of association did not 
differ by IGF-1 concentration.  
CONCLUSIONS: Adult height was associated with risk of several cancer sites. However, 
some of these associations were sex specific. There was no strong evidence to support 
IGF-1 moderating the association between height and cancer.  
Keyword: cancer, height, insulin-like growth factors   
INTRODUCTION 
Although simple to measure, height is a complex phenotype that is downstream of 
multiple biological and sociological determinants.1 Height has been associated with many 
chronic diseases including cardiovascular diseases and cancer. Although height has a 
strong genetic component,2,3 the environment, especially economic development and 
nutrition, play a major role in determining our height.1 Recent evidence suggests that 
changes in a population's height also correlates with cancer estimates.4  
Height has been robustly associated with a higher risk for many cancer sites, with most 
of this evidence derived from prospective cohort studies,2,5,6 but also recently from 
Mendelian Randomization (MR) studies.2,3,7 The last report from the World Cancer 
Research Fund (WCRF) showed that eight cancer-sites are positively associated with 
height (colorectum, breast, ovary, pancreas, endometrium, prostate, kidney and skin). 
However, five of these cancer sites have been labelled as having "probable evidence", 
therefore further research is required.6 A recent study, published for Choi et al., 
investigated the association between height and cancer risk in a cohort of 23 million 
Korean adults. 8 This study reported an increased risk of cancers of the nervous system, 
thyroid, breast, lung, colon, rectum, prostate, ovary, testes, cervix, endometrium, skin, 
lymphoma, multiple myeloma and leukaemia. 8  
However, the mechanism underpinning how height confers a higher risk of cancer is 
complex because the biological determinants of height are multifactorial. Despite this, 
several hypotheses have been proposed: one of them relates to insulin-like growth factor 
(IGF-1), which has a direct effect on increasing cancer risk but also height. 9 IGF-1 is one 
of the most important determinants of height and organ size and it has been postulated 
as a potential moderator of the link between height and cancer risk. 10,11 A second 
hypothesis suggests that the increased risk conferred by height is attributable to more 
cells in taller, compared with shorter, people.12-14 Taller individuals have more stem cells 
and therefore they are exposed to a higher number of cell divisions during which driver 
mutations may occur.11,13,14 Moreover, the higher IGF-1 concentration and higher number 
of cells in taller people could, at least partly, explain differences in the cancer risk 
observed between men and women. However, whether IGF-1 modifies the association 
between height and cancer risk has not been fully elucidated. 11 Therefore, by using the 
UK Biobank prospective cohort study we aim to investigate the sex-specific association 
between height and 24 site-specific cancers to assess whether the association differed 
by circulating concentrations of IGF-1. 
METHODS 
Data sources 
502 536 participants (aged 37-73 years, 56.3% were women) were recruited into UK 
Biobank between 2006 and 2010. Participants attended one of 22 assessment centres 
across England, Scotland, and Wales, where they completed a touch screen 
questionnaire, had physical measurements taken, and provided biological samples, as 
described in detail elsewhere. 15,16 The outcomes in the study reported here were 
incidence of and mortality from 24 site-specific cancers, with the exposure variable being 
height (expressed in 5 cm increment). We treated sociodemographic factors (age, 
ethnicity, and area based socioeconomic status), smoking status, waist circumference, 
and self-reported physical activity, sedentary time, sleep and dietary intake as potential 
confounders, as well as prevalent comorbidities at baseline (diabetes, hypertension, 
cardiovascular diseases and longstanding illness). After excluding participants with 
prevalent cancer at baseline (n=41 437) and those with missing data on covariates, 
exposures or outcomes (n= 46 176), 414 923 (82.6%) participants with full data available 
were included in this study.  
Procedures  
The outcomes for this study were cancer incidence and mortality; overall and for 24 site-
specific cancers. Date and cause of death was obtained from death certificates held 
within the National Health Service Information Centre (England and Wales) and the 
National Health Service Central Register Scotland (Scotland). Dates and cause of 
hospital admissions were obtained from the Health Episode Statistics (England and 
Wales) and Scottish Morbidity Records (Scotland). Detailed information about the record 
linkage procedures can be found at http://content.digital.nhs.uk/services. Incident cancer 
was defined as the first record of the cancer of interest, from hospitalisation or death 
records. At the time of analysis, mortality data were available up to 14 February 2018. 
Mortality analyses were therefore censored at this date or date of death, whichever 
occurred earlier. Hospital admission data were available until 31 March 2017. Therefore, 
analyses of incident cancer were censored at this date, or the date of first hospitalisation 
for the cancer of interest or death, whichever occurred earlier.  
The International Classification of Diseases, 10th revision (ICD-10) was used to define 
the following 24 cancer-specific sites: all cancers (C00-C97, D37, D48), brain (C71), oral 
(C00-C14 ), oesophagus (C15), stomach (C16), liver (C22),  gallbladder (C23), pancreas 
(C25), lung (C34), colorectal (C18, C19, and C20), kidney (C64-C65), bladder (C67), 
thyroid (C73), lymphatic and hematopoietic tissue (C81-C96), non-Hodgkin lymphoma 
(C82-C85), multiple myeloma (C90), malignant melanoma (C43), leukaemia (C91-C95), 
prostate (C61), testis (C62), breast (C50), ovary (C56), endometrium (C54), uterine (C55) 
and cervix (C53). Of these, 20 cancer sites were used for men and women, two sites 
were specific to men (testis and prostate) and five to women (breast, endometrium, 
uterine, cervix and ovary).  
Exposure 
Height was measured at baseline by trained staff using standardised protocols and a 
Seca 202 device (Seca, Hamburg, Germany). 
Covariables 
Potential confounders were identified a priori based on established relationships, with 
cancer and height (Supplementary figure 1). Age, ethnicity, smoking status (non-
smokers, ex-smokers and current smokers), dietary intake of major food groups, alcohol 
intake and female-specific factors were self-reported at the baseline assessment via a 
touch-screen questionnaire. Comorbidities and past medical history were based on self-
report of physician diagnosis and verified during the face-to-face interview. Townsend 
area deprivation index was derived from the postcode of residence using aggregated 
data on unemployment, car and homeownership, and household overcrowding, and was 
categorised into tertiles (low, middle and high) 17. Physical activity level over a typical 
week was self-reported using the International Physical Activity Questionnaire and 
analysed as metabolic equivalent of task (MET) per week. 18 Sedentary behaviour 
included time spent watching TV or in front of a PC at leisure time. Sleep time was also 
self-reported and categorised in short (<7 h/day), normal (7-9 h/day) and long sleepers 
(>9 h/day). Waist circumference was measured by trained nurses using a standard 
protocol. In initial assessment visit (2006-2010), 467,041 participants were recruited and 
consent. Serum concentrations of insulin-like growth factor-1 (IGF-1) were measured 
using a DiaSorin Ltd (Beckman Coulter DXI 800) chemiluminescent immunoassay.  The 
IGF-1 assays were externally validated with good correlation and coefficient of variations 
were consistent across samples.19 Further details of these measurements can be found 
in the UK Biobank online protocol (http://www.ukbiobank.ac.uk). 
Statistical analyses 
Cox proportional hazard models with follow-up time as the time-dependent variable were 
used to investigate sex-specific associations of height with incidence and mortality for 24 
cancer sites and all-cause cancer. All analyses excluded participants who reported 
prevalent cancer at baseline. To minimise the potential contribution of reverse causality 
to the findings, we conducted a landmark analysis excluding people who had events 
within the two years after recruitment.  
Descriptive variables are presented as mean and standard deviation for continuous 
variables and number and percentage of participants for categorical variables. Pearson 
correlation were performed to investigate the associations of IGF-1 with age and height 
by sex. To investigate whether the concentration of IGF-1 by age and height differed by 
sex, we interaction terms (age*sex and height*sex) were included in our linear regression 
models.      
Sex-specific associations between height (expressed per 5 cm increment) and cancer 
outcomes were studied using Cox-proportional hazard models for both females and 
males independently. Results were reported as hazard ratios and their 95% CI. All 
analyses were incrementally adjusted for the following covariates: Model 1 included age, 
ethnicity, deprivation, and comorbidity (including prevalent hypertension, cardiovascular 
diseases, diabetes and long-standing illness); Model 2 included model 1 plus smoking, 
alcohol consumption, fruit and vegetables, processed meat, oily fish intake, sleep, 
physical activity and sedentary behaviours, and Model 3 (fully adjusted) included 
variables from model 2 plus waist circumference.  
To investigate differences on cancer risk between sex, Men-to-women hazard ratios were 
then estimated using Cox models with height:sex interaction terms. This term represents 
the statistical interaction between sex and the predictor and can be interpreted as the 
ratio of HR between men to women ratio of HR.  
To investigate whether the association between height and cancer differed by IGF-1 we 
fitted an interaction term between height (per 5 cm) and age- and sex-standarised IGF-1 
concentration. We also investigated whether the association between 5-cm increment in 
height and cancer differed by height (shorter or taller) by stratifying the analyses using 
the the sex-specific median of height as the cut-off: above or below 162 cm for women 
and 176 cm for men. We also conducted sensitivity analyses for lung and women-specific 
cancers. The association of height with lung cancers were stratified by smoking status 
(current, ex-smoker and non-smoker). For women, the association between height and 
cervix, ovary, uterus, breast and endometrium cancers were stratified by pre and 
postmenopausal status. Additionally, stomach and liver cancers were stratified by 
reported alcohol consumption (≤1 per week versus >1 per week). Finally, because of 
potentially inflated type-I errors due to multiple tests, All analyses were corrected for 
multiple testing using Holm’s method, 20 which performed similarly as Bonferroni’s 
method while retaining higher statistical power. 21 The multiple testing corrected p-value 
are denoted as Padj. 
All analyses were performed using R Statistical Software version 3.6.2 with the package 
survival. The proportional hazard assumption was verified by tests based on Schoenfeld 
residuals.  
RESULTS 
Characteristics of the study population 
Of the 502 536 participants enrolled in UK Biobank, 414 923 were included in the current 
study. The median follow-up period was 6.03 (range 5.3 to 6.7) years for cancer incidence 
and 6.9 (range 6.3 to 7.5) years for cancer mortality. Over the follow-up period, 22 647 
participants developed cancer and 4,539 died from it.  
Baseline characteristics at baseline were described by sex in Table 1. The mean age was 
53.6% were women and 94.8% were of White-European ethnic background. The mean 
of height was 1.69 cm (1.76 cm and 1.62 cm for men and women, respectively). The 
mean concentration of IGF-1 were 21.1 and 21.9 nmol/L for women and men, 
respectively. The Pearson correlation coefficient between IGF-1 and height was r=0.118 
and r=0.107 for men and women, respectively (Supplementary Table S1). The 
associations of IGF-1 with age and height by sex are shown in Supplementary Figures 
S2 and S3. In summary, IGF-1 concentration decreased in a linear manner with age for 
both men and women. However, the reduction in IGF was higher in women than men 
with increasing age (p-interaction <0.0001) (Supplementary Figure S2). In contrast, IGF-
1 concentration increased in a linear fashion with increasing height, with no differences 
between men and women (p-interaction=0.114) (Supplementary Figure S3).  
Height and cancer risk  
In men, after correction for multiple testing, height was positively associated with 
increased risk of incident cancer overall and at five sites (lung, lymphatic, non-Hodgkins 
lymphoma, melanoma and leukaemia). The hazard ratios of these associations per 5-cm 
higher height ranged between 1.01 and 1.05 (Figure 1). Similar magnitudes of association 
were observed in women for breast cancer, melanoma, lymphatic and non-Hodgkin 
lymphomas and all-cause cancer (Figure 2). For cancer mortality, the associations 
became non-significant after controlling for multiple testing (Figure 1). For women, only 
all-cause cancer remained significant after controlling for multiple comparisons (Figure 
2). The associations were similar in the three models studied (Supplementary Table S2 
and S3).  
Sex differences in the association of height and cancer 
When adjusted for multiple testing, compared to men, women had a higher risk of incident 
all-cause cancer (HR: 0.99, 95% CI: 0.99; 0.99) per 5-cm higher height. No other 
differences in cancer risk were found between men and women (Figure 3).  
Sensitivity analysis 
In a sensitive analysis height was associated with breast cancer incidence in both 
premenopausal and postmenopausal women with similar effect sizes (HR 1.02, 95% 
CI:1.01; 1.02) and 1.02, 95%CI: 1.00; 1.02) respectively, Pinteraction 0.936) (Supplementary 
Table S4). Sensitivity analyses by smoking status are presented in Supplementary Table 
S5. Height was associated with lung cancer in current and ex-smokers (Pinteraction 0.720). 
Although similar hazard ratios were observed for smokers and non-smokers, these 
associations were no significant. Height was associated with liver cancer mortality only 
among women, no differences were found between those who consumed < or ≥ once a 
week (Supplementary Table S6).  
When association between height and cancer was further stratified by tall v/s short 
individuals, no differences were observed among men for leukaemia, melanoma, non-
Hodking lymphoma, lungand all-cause cancer (Supplementary Table S7). The 
association were lost when the analyses were adjusted for multiple testing 
(Supplementary Table S7).  
Moderator analysis by IGF-1 
For men, the interaction between IGF-1 and cancer incidence is presented in Figure 4. 
IGF-1 did not modify the association between height and cancer incidence. HR of height 
among high IGF-1 group is presented in Supplementary Table S8. Similar results were 
found for women, no difference in the association were showed by IGF-1 levels (Figure 
4, Supplementary Figure S4, Table S9). 
DISCUSSION 
The main findings of this study corroborate the associations of height with increased 
incidence risk of different cancer sites and overall cancer in men and women. However, 
some of these associations differ by sex. Women have a higher incidence risk than men 
for all-cause cancer. We also provide evidence that circulating concentrations of IGF-1 
do not modify the association between height and cancer incidence and mortality.  
Our findings are in line with previous prospective cohort evidence that suggests that 
height is associated with a higher risk of postmenopausal breast cancer, melanoma, non-
Hodgkin lymphoma, lymphatic cancer and leukaemia.5,6,8 However, we did not 
corroborate the association of height with colorectal, ovary, endometrium pancreas, 
prostate and kidney cancer. However, the magnitude and direction of the associations 
observed in our study agreed with previous evidence.8 Therefore, the lack of significant 
association may be related to a lack of power rather than a lack of association. For all 
cause cancer Choi et al found HR: 1.088 (95% CI:1.086; 1.090), similar to our results: 
HR: 1.008 (95% CI: 1.005; 1.010) for men 1.010 (95% CI: 1.008; 1.013) for women. 
Although our findings are in agreement with evidence derived from prospective 
studies,5,6,8 these associations do not imply causality. An MR study reported a positive 
association for 17 cancers sites, only six (kidney, non-Hodgkin, colorectal, lung, 
melanoma and breast cancer) of these cancer sites were significantly associated with 
height.22 Another MR study conducted in UK Biobank participants found a positive 
association between height and colorectal, endometrium and ovary cancer.3 We did 
observe an association with colorectal cancer in minimally adjusted models however, no 
associations were observed for ovary and endometrium cancer in the fully adjusted 
models. Besides, the magnitude of the association reported by our study were smaller 
than those reported by MR studies.3,22 These differences between studies may be related 
to residual confounding or reverse causality, as well as effect sizes from MR studies 
representing a lifelong cumulative risk or lifelong exposure.   
Evidence behind the associations of height with non-Hodgkins lymphoma, melanoma and 
leukaemia has been controversial. However, MR studies have provided evidence that the 
link between height and these cancers is causal. However, the exact mechanism behind 
these associations has not been fully elucidated. Some hypotheses suggests that genetic 
or early environment exposures may play a role in the link between height and these 
cancers.23 Height during adulthood may reflect cumulative exposure to hormones/growth 
factors and nutritional status in early life.5 However, it is biologically plausible that height 
may indirectly influence carcinogenesis through IGF-1 pathways or immune pathways. 
The IGF-1 pathways could be triggered by overnutrition, particularly by higher intake of 
energy-dense foods.24 Moreover, recent studies have provided evidence that supports 
an association between IGF-1 and the risk of several cancers.9,25,26 IGF-1 concentration 
is an important determinant of height and may be a determinant of organ size, and thus 
IGF-1 could be related to cancer through greater cell division.27 Moreover, taller 
individuals have a greater number of cells, that are susceptible to conversion into 
neoplastic cells.28 However, more research is necessary to understand the underlying 
mechanism. 
Strengths and limitations 
The strength of the paper is the comprehensive analysis of height and cancer stratified 
by sex, in one large cohort. Observational studies cannot determine causality, with 
confounding and reverse causation, However, to minimise the effect of reverse causation 
in our study, we excluded all participants with a self-reported medical history of cancer at 
baseline and those new cancer diagnoses within the first 2-years of follow up. UK Biobank 
is not representative of the general population; therefore, caution should be taken in 
generalising summary statistics to the general population, but estimates of the magnitude 
of the associations are generalisable.29 Some of the sample sizes for cancer-specific sites 
were small (less than 30), therefore the association should be interpreted with caution. 
Our hazard estimate compares to MR study results share a similar trend but a smaller 
magnitude of the association.3,22 However, we did not find an association between height 
and cancers of the ovary and endometrium. Some of the conflicting results could be 
explained by a lack of power for some rare cancers with wide confidence intervals in our 
study and the MR evidence. 
CONCLUSION 
Height was positively associated with an increased risk of several cancer sites in men 
and women. However, women have a higher risk than men for all-cause cancer. IGF-1 
does not modify the associations between height and cancer risk.   
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TABLE LEGENDS 
Table 1:  Characteristics of participants  
 
Females Males Overall 
n (%) 222 635 (53.6%) 192 288 (46.3%) 414 923 
Age (years), mean (SD) 56.1 (8.0) 56.5 (8.2) 56.3 (8.1) 
IGF1 (nmol/L), mean (SD) 21.1 (5.8) 21.9 (5.5) 21.5 (5.7) 
Townsend deprivation index, n (%) 
   
Lower  75 311 (33.8%) 65 557 (34.1%) 140 868 (34.0%) 
Middle 75 622 (34.0%) 63 654 (33.1%) 139 276 (33.6%) 
Higher  71 702 (32.2%) 63 077 (32.8%) 134 779 (32.5%) 
Ethnicity, n (%) 
   
White 211 041 (94.8%) 182 334 (94.8%) 393 375 (94.8%) 
Mixed 3 532 (1.6%) 2 529 (1.3%) 6 061 (1.5%) 
South Asian 3 645 (1.6%) 4 309 (2.2%) 7 954 (1.9%) 
Black 3 613 (1.6%) 2 622 (1.4%) 6 235 (1.5%) 
Chinese 804 (0.4%) 494 (0.3%) 1 298 (0.3%) 
Height (m), mean (SD) 1.62 (0.1) 1.76 (0.1) 1.69 (0.1) 
Weight (Kg), mean (SD) 71.3 (14.0) 85.9 (14.2) 78.1 (15.9) 
Waist (cm), mean (SD) 84.5 (12.4) 96.8 (11.2) 90.2 (13.4) 
Body Mass index (kg/m2) , mean (SD) 27.0 (5.1) 27.8 (4.2) 27.4 (4.7) 
Nutritional status, n (%)    
            Underweight 1 629 (0.7%) 427 (0.2%) 2 056 (0.5%) 
            Normal 87 856 (39.5%) 48 179 (25.1%) 136 035 (32.8%) 
            Overweight 81 755 (36.7%) 95 382 (49.6%) 177 137 (42.7%) 
            Obese 51 395 (23.1%) 48 300 (25.1%) 99 695 (24.0%) 
Smoking, n (%) 
   
Never 133 852 (60.1%) 95 290 (49.6%) 229 142 (55.2%) 
Ex-Smoker 69 315 (31.1%) 73 403 (38.2%) 142 718 (34.4%) 
Current 19 468 (8.7%) 23 595 (12.3%) 43 063 (10.4%) 
Alcohol intake, n (%) 
   
Daily or almost daily 36 136 (16.2%) 49 101 (25.5%) 85 237 (20.5%) 
3-4 times a week 46 471 (20.9%) 51 095 (26.6%) 97 566 (23.5%) 
Once or twice a week 57 861 (26.0%) 49 894 (25.9%) 107 755 (26.0%) 
1-3 times a month 29 211 (13.1%) 17 053 (8.9%) 46 264 (11.2%) 
Special occasions only 32 745 (14.7%) 13 614 (7.1%) 46 359 (11.2%) 
Never 20 211 (9.1%) 11 531 (6.0%) 31 742 (7.7%) 
Sleep time, n (%) 
   
Normal 7-9h.day 165 418 (74.3%) 140 733 (73.2%) 306 151 (73.8%) 
Short sleep <7h.day 53 339 (24.0%) 48 480 (25.2%) 101 819 (24.5%) 
Long sleep >9h.day 3 878 (1.7%) 3 075 (1.6%) 6 953 (1.7%) 
Sedentary time (h/day), mean (SD) 4.66 (2.0) 5.46 (2.5) 5.03 (2.3) 
Physical activity (MET h/week) mean (SD) 1.78 (1.7) 1.86 (1.6) 1.82 (1.7) 
Diabetes, n (%) 7 185 (3.2%) 12 823 (6.7%) 20 008 (4.8%) 
Hypertension, n (%) 50 661 (22.8%) 57 155 (29.7%) 107 816 (26.0%) 
CVD, n (%) 55 743 (25.0%) 64 937 (33.8%) 120 680 (29.1%) 
Long-standing illness, n (%) 156 193 (70.2%) 124 823 (64.9%) 281 016 (67.7%) 
 
Data are presented as number of participants and their percentage (%) for categorical 
variables. Continuous variables are presented as mean and standard deviation. Data 
available for 414 923. 
  
 
Figure 1. Association of height with the risk of incidence and mortality from 20 cancer 
sites in men. 
Data presented as hazard ratio and their 95% CI per 5-cm increment in height. analyses 
were adjusted for age, sex, ethnicity, deprivation index, comorbidity, smoking, alcohol 
consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical activity, 




Figure 2. Association of height with the risk of incidence and mortality from 22 cancer 
sites in women. 
Data presented as hazard ratio and their 95% CI per 5-cm increment in height. Analyses 
were adjusted for age, sex, ethnicity, deprivation index, comorbidity, smoking, alcohol 
consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical activity, 




Figure 3. Ratios of HR of women to men for the association of height with incidence and 
mortality of 18 cancer sites. 
Data presented as ratio of HR (interaction term sex and height) and their 95% CI per 5-
cm increment in height. Models were adjusted for age, ethnicity, deprivation index, 
comorbidity, smoking, alcohol consumption, fruit & vegetable, processed meat intake, oil 
and fish, sleep, physical activity, sedentary behaviours and waist circumference. 
  
 
Figure 4. Ratio of HR of low to high IGF-1 level for the association of height with incidence 
of 24 cancer sites men and women. 
Data presented as ratio of hazard ratio (interaction term of IGF-1 level and height) and 
their 95% CI per 5-cm increment in height. Models were adjusted for age, ethnicity, 
deprivation index, comorbidity, smoking, alcohol consumption, fruit & vegetable, 




Supplementary material: Does insulin-like growth factor moderate the association between height and risk of cancer 













Supplementary Figure S1: Directed Acyclic Graphs Potential confounders identified a priori based on established 
relationships, with cancer and height. 
Sociodemographic factors: age, ethnicity, deprivation, Lifestyle factors: diet (fruits and vegetables, oily fish, 
alcohol, red and process meat intake), sleep, physical activity and sedentary behaviour.  
  
Supplementary Table S1: Person Correlation IGF-1 and height by age and sex 
 Both sex  Men  Women  
Height and 
IGF-1 Coefficient P value Coefficient P value Coefficient P value 
Overall 0.133 <0.001 0.118 <0.001 0.107 <0.001 
<45 years 0.038 <0.001 0.106 <0.001 0.070 <0.001 
45-50 years 0.083 <0.001 0.108 <0.001 0.080 <0.001 
50-55 years 0.116 <0.001 0.095 <0.001 0.070 <0.001 
55-60 years 0.119 <0.001 0.084 <0.001 0.050 <0.001 
60-65 years 0.130 <0.001 0.082 <0.001 0.047 <0.001 
>65 years 0.136 <0.001 0.066 <0.001 0.034 <0.001 






Supplementary Figure S2: IGF-1 blood concentration by age and sex.   
 
 
Supplementary Figure S3: IGF-1 blood concentration by height and sex.   
  
Supplementary Table S2: Association height (per 5 cm) and cancer risk incidence, men and women.  
Site cancer Total Event Model 1 P-
value 
Padjusted Model 2 P-
value 
Padjusted Model 3 P-value Padjusted 
MEN 
All-cause 188,694 14,839 1.01 (1.01; 1.01) <0.001 <0.001 1.01 (1.01; 1.01) <0.001 <0.001 1.01 (1.01; 1.01) <0.001 <0.001 
Bladder 192,056 848 1.01 (1.00; 1.02) 0.288 1.00 1.01 (1.00; 1.02) 0.230 1.00 1.00 (0.99; 1.01) 0.492 1.00 
Brain 192,222 260 1.01 (0.99; 1.03) 0.241 1.00 1.01 (0.99; 1.03) 0.254 1.00 1.01 (0.99; 1.03) 0.204 1.00 
Colorectal 191,867 1,503 1.00 (1.00; 1.01) 0.360 1.00 1.00 (1.00; 1.01) 0.378 1.00 1.00 (0.99; 1.01) 0.835 1.00 
Gallbladder 192,282 23 0.95 (0.89; 1.01) 0.094 1.00 0.95 (0.89; 1.01) 0.083 1.00 0.94 (0.88; 1.00) 0.057 0.741 
Kidney 192,196 436 1.00 (0.99; 1.02) 0.484 1.00 1.01 (0.99; 1.02) 0.347 1.00 1.00 (0.99; 1.02) 0.852 1.00 
Leukaemia 192,227 350 1.03 (1.01; 1.05) <0.001 <0.001 1.03 (1.01; 1.05) <0.001 <0.001 1.03 (1.01; 1.05) <0.001 <0.001 
Liver 192,253 220 0.99 (0.97; 1.01) 0.405 1.00 0.99 (0.97; 1.01) 0.552 1.00 0.99 (0.97; 1.01) 0.205 1.00 
Lung 192,076 1,026 1.01 (1.00; 1.02) 0.069 0.897 1.01 (1.00; 1.02) 0.005 0.075 1.02 (1.01; 1.02) 0.001 0.016 
Lymphatic 192,052 1,092 1.02 (1.01; 1.03) <0.001 <0.001 1.02 (1.01; 1.03) <0.001 <0.001 1.02 (1.01; 1.03) <0.001 <0.001 
Melanoma 192,171 556 1.03 (1.02; 1.04) <0.001 <0.001 1.03 (1.02; 1.04) <0.001 <0.001 1.03 (1.01; 1.04) <0.001 <0.001 
Multiple 
Myeloma 192,241 228 1.01 (0.99; 1.03) 0.212 
1.00 
1.01 (0.99; 1.03) 0.215 
1.00 
1.01 (0.99; 1.03) 0.262 
1.00 
Non-Hodgkin 192,165 524 1.02 (1.01; 1.03) 0.002 0.032 1.02 (1.01; 1.03) 0.001 0.016 1.02 (1.01; 1.04) 0.001 0.016 
Oesophagus 192,190 408 0.98 (0.97; 1.00) 0.039 
0.585 
0.99 (0.97; 1.00) 0.097 
1.00 
0.98 (0.97; 1.00) 0.010 
0.140 
Oral 192,215 311 1.00 (0.98; 1.01) 0.795 1.00 1.00 (0.98; 1.02) 0.872 1.00 1.00 (0.98; 1.02) 0.919 1.00 
Pancreas 192,229 364 1.02 (1.00; 1.03) 0.043 0.602 1.02 (1.00; 1.03) 0.052 0.728 1.01 (1.00; 1.03) 0.105 1.00 
Prostate 191,529 3,566 1.00 (1.00; 1.01) 0.357 1.00 1.00 (1.00; 1.01) 0.500 1.00 1.00 (1.00; 1.01) 0.243 1.00 
Stomach 192,216 314 1.00 (0.98; 1.01) 0.597 1.00 1.00 (0.98; 1.01) 0.802 1.00 0.99 (0.97; 1.01) 0.279 1.00 
Testis 192,275 56 1.04 (1.00; 1.08) 0.076 0.912 1.03 (1.00; 1.07) 0.080 1.00 1.03 (1.00; 1.08) 0.082 0.984 
Thyroid 192,276 43 1.02 (0.97; 1.06) 0.415 1.00 1.01 (0.97; 1.06) 0.556 1.00 1.01 (0.97; 1.06) 0.594 1.00 
WOMEN 
All-cause 219,073 13,844 1.01 (1.01; 1.01) <0.001 <0.001 1.01 (1.01; 1.01) <0.001 <0.001 1.01 (1.01; 1.01) <0.001 <0.001 
Bladder 222,561 278 1.00 (0.98; 1.02) 0.940 1.00 1.00 (0.98; 1.02) 0.899 1.00 1.00 (0.98; 1.02) 0.842 1.00 
Brain 222,595 171 1.00 (0.98; 1.03) 0.887 1.00 1.00 (0.98; 1.02) 0.993 1.00 1.00 (0.98; 1.02) 0.988 1.00 
Breast 221,450 4,283 1.02 (1.01; 1.02) <0.001 <0.001 1.02 (1.01; 1.02) <0.001 <0.001 1.01 (1.01; 1.02) <0.001 <0.001 
Cervix 222,613 50 0.98 (0.93; 1.02) 0.292 1.00 0.98 (0.94; 1.03) 0.413 1.00 0.98 (0.94; 1.02) 0.377 1.00 
Colorectal 222,368 1,142 1.01 (1.00; 1.02) 0.193 1.00 1.01 (1.00; 1.02) 0.116 1.00 1.01 (1.00; 1.02) 0.186 1.00 
Endometrium 222,491 646 0.99 (0.98; 1.00) 0.242 1.00 1.00 (0.98; 1.01) 0.500 1.00 0.99 (0.98; 1.00) 0.056 0.952 
Gallbladder 222,628 44 1.03 (0.98; 1.08) 0.280 1.00 1.03 (0.98; 1.08) 0.236 1.00 1.03 (0.98; 1.08) 0.298 1.00 
Kidney 222,583 234 1.00 (0.98; 1.02) 0.881 1.00 1.00 (0.98; 1.02) 0.777 1.00 1.00 (0.98; 1.02) 0.882 1.00 
Leukaemia 222,600 200 1.03 (1.01; 1.06) 0.004 0.072 1.03 (1.01; 1.06) 0.003 0.054 1.03 (1.01; 1.06) 0.004 0.072 
Liver 222,610 156 1.02 (1.00; 1.05) 0.115 1.00 1.02 (1.00; 1.05) 0.072 1.00 1.02 (1.00; 1.05) 0.086 1.00 
Lung 222,478 881 1.00 (0.99; 1.01) 0.719 1.00 1.00 (0.99; 1.02) 0.399 1.00 1.00 (0.99; 1.01) 0.468 1.00 
Lymphatic 222,467 835 1.03 (1.01; 1.04) <0.001 <0.001 1.03 (1.02; 1.04) <0.001 <0.001 1.03 (1.02; 1.04) <0.001 <0.001 
Melanoma 222,492 543 1.02 (1.01; 1.04) 0.001 0.019 1.02 (1.01; 1.04) 0.001 0.019 1.02 (1.01; 1.04) 0.001 0.019 
Multiple 
Myeloma 222,602 188 1.02 (1.00; 1.04) 0.111 
1.00 
1.02 (1.00; 1.05) 0.050 
0.800 
1.02 (1.00; 1.04) 0.071 
1.00 
Non-Hodgkin 222,535 438 1.03 (1.01; 1.04) <0.001 <0.001 1.03 (1.01; 1.05) <0.001 <0.001 1.03 (1.01; 1.05) <0.001 <0.001 
Oesophagus 222,602 135 1.01 (0.98; 1.04) 0.544 1.00 1.01 (0.98; 1.04) 0.494 1.00 1.01 (0.98; 1.04) 0.469 1.00 
Oral 222,597 164 0.98 (0.96; 1.01) 0.185 1.00 0.98 (0.96; 1.01) 0.172 1.00 0.98 (0.96; 1.01) 0.204 1.00 
Ovary 222,502 515 1.01 (0.99; 1.02) 0.355 1.00 1.01 (0.99; 1.02) 0.318 1.00 1.01 (0.99; 1.02) 0.306 1.00 
Pancreas 222,583 299 1.01 (0.99; 1.03) 0.211 1.00 1.01 (0.99; 1.03) 0.204 1.00 1.01 (0.99; 1.03) 0.260 1.00 
Stomach 222,611 120 1.01 (0.98; 1.04) 0.392 1.00 1.01 (0.99; 1.04) 0.320 1.00 1.01 (0.98; 1.04) 0.378 1.00 
Thyroid 222,598 113 1.03 (1.00; 1.06) 0.062 1.00 1.03 (1.00; 1.06) 0.047 0.799 1.03 (1.00; 1.06) 0.077 1.00 
Uterine 222,448 713 0.99 (0.98; 1.01) 0.285 1.00 1.00 (0.99; 1.01) 0.582 1.00 0.99 (0.98; 1.00) 0.072 1.00 
Data is presented as hazard ratio (HR) and their 95% confidence interval (95% CI) in men and women, Padjusted: P-value adjusted for multiple testing 
Model 1: Adjusted for age, ethnicity, deprivation index and comorbidity. 
Model 2; Adjusted for model 1 plus smoking, alcohol consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical activity and sedentary behaviours. 




Supplementary Table S3: Association height (per 5 cm) and cancer risk mortality, men and women.   
Site cancer Total Event Model 1 P-
value 
Padjusted Model 2 P-
value 
Padjusted Model 3 P-value Padjusted 
MEN 
All-cause 191,881 3,986 1.01 (1.00; 1.01) 0.019 0.361 1.01 (1.00; 1.01) 0.001 0.019 1.01 (1.00; 1.01) 0.013 0.247 
Bladder 192,284 139 1.01 (0.98; 1.03) 0.522 1.00 1.01 (0.99; 1.04) 0.432 1.00 1.01 (0.98; 1.03) 0.536 1.00 
Brain 192,254 231 1.01 (0.99; 1.03) 0.560 1.00 1.01 (0.99; 1.02) 0.592 1.00 1.01 (0.99; 1.03) 0.470 1.00 
Colorectal 192,254 417 1.01 (1.00; 1.02) 0.200 1.00 1.01 (0.99; 1.02) 0.211 1.00 1.00 (0.99; 1.02) 0.654 1.00 
Gallbladder 192,284 14 0.93 (0.86; 1.00) 0.059 1.00 0.93 (0.86; 1.00) 0.056 0.952 0.92 (0.85; 1.00) 0.038 0.570 
Kidney 192,273 153 1.00 (0.98; 1.02) 0.981 1.00 1.00 (0.98; 1.03) 0.797 1.00 1.00 (0.97; 1.02) 0.878 1.00 
Leukaemia 192,275 160 1.02 (1.00; 1.04) 0.082 1.00 1.02 (1.00; 1.05) 0.064 0.96 1.02 (1.00; 1.05) 0.062 0.868 
Liver 192,272 155 1.00 (0.98; 1.02) 0.928 1.00 1.00 (0.98; 1.03) 0.754 1.00 1.00 (0.97; 1.02) 0.720 1.00 
Lung 192,194 790 1.01 (1.00; 1.02) 0.295 1.00 1.01 (1.00; 1.02) 0.058 0.952 1.01 (1.00; 1.02) 0.018 0.324 
Lymphatic 192,250 380 1.02 (1.00; 1.03) 0.024 0.432 1.02 (1.00; 1.03) 0.013 0.234 1.02 (1.00; 1.03) 0.020 0.340 
Melanoma 192,283 64 1.02 (0.98; 1.05) 0.418 1.00 1.02 (0.98; 1.05) 0.384 1.00 1.02 (0.98; 1.05) 0.417 1.00 
Multiple 
Myeloma 192,282 54 1.03 (0.99; 1.07) 0.114 
1.00 
1.03 (0.99; 1.07) 0.126 
1.00 
1.03 (0.99; 1.07) 0.175 
1.00 
Non-Hodgkin 192,271 157 1.01 (0.98; 1.03) 0.525 1.00 1.01 (0.99; 1.03) 0.365 1.00 1.01 (0.99; 1.03) 0.414 1.00 
Oesophagus 192,263 262 0.98 (0.97; 1.00) 0.080 
1.00 
0.99 (0.97; 1.01) 0.182 
1.00 
0.98 (0.96; 1.00) 0.025 
0.400 
Oral 192,285 73 1.00 (0.97; 1.04) 0.811 1.00 1.01 (0.98; 1.04) 0.620 1.00 1.01 (0.98; 1.05) 0.427 1.00 
Pancreas 192,246 306 1.01 (1.00; 1.03) 0.102 1.00 1.01 (1.00; 1.03) 0.110 1.00 1.01 (0.99; 1.03) 0.237 1.00 
Prostate 192,273 342 1.01 (1.00; 1.03) 0.150 1.00 1.01 (1.00; 1.03) 0.122 1.00 1.01 (0.99; 1.03) 0.268 1.00 
Stomach 192,270 131 1.01 (0.99; 1.04) 0.400 1.00 1.02 (0.99; 1.04) 0.238 1.00 1.01 (0.98; 1.04) 0.474 1.00 
Testis 192,273 0 NA.  1.00 NA.  1.00 NA.   1.00 
Thyroid 192,288 5 0.99 (0.87; 1.13) 0.903 1.00 0.99 (0.86; 1.13) 0.843 1.00 0.97 (0.85; 1.11) 0.705 0.247 
WOMEN 
All-cause 222,386 2,969 1.01 (1.00; 1.02) 0.001 0.023 1.01 (1.01; 1.02) <0.001 <0.001 1.01 (1.00; 1.02) 0.001 0.023 
Bladder 222,631 35 1.00 (0.95; 1.06) 0.857 1.00 1.01 (0.95; 1.06) 0.811 1.00 1.00 (0.95; 1.06) 0.954 1.00 
Brain 222,619 145 1.00 (0.98; 1.03) 0.817 1.00 1.00 (0.98; 1.03) 0.857 1.00 1.00 (0.98; 1.03) 0.819 1.00 
Breast 222,621 272 1.02 (1.00; 1.04) 0.025 0.550 1.02 (1.00; 1.04) 0.035 0.735 1.02 (1.00; 1.04) 0.055 1.00 
Cervix 222,633 10 0.96 (0.87; 1.06) 0.373 1.00 0.96 (0.87; 1.06) 0.457 1.00 0.97 (0.88; 1.07) 0.518 1.00 
Colorectal 222,618 296 1.01 (0.99; 1.03) 0.188 1.00 1.01 (1.00; 1.03) 0.123 1.00 1.01 (0.99; 1.03) 0.156 1.00 
Endometrium 222,633 69 1.01 (0.97; 1.05) 0.750 1.00 1.01 (0.97; 1.05) 0.634 1.00 1.00 (0.96; 1.04) 0.997 1.00 
Gallbladder 222,634 24 1.02 (0.96; 1.09) 0.519 1.00 1.02 (0.96; 1.09) 0.476 1.00 1.02 (0.96; 1.09) 0.544 1.00 
Kidney 222,627 51 0.99 (0.94; 1.03) 0.568 1.00 0.99 (0.94; 1.03) 0.594 1.00 0.98 (0.94; 1.03) 0.405 1.00 
Leukaemia 222,623 78 1.03 (1.00; 1.07) 0.080 1.00 1.03 (1.00; 1.07) 0.080 1.00 1.03 (0.99; 1.07) 0.111 1.00 
Data is presented as hazard ratio (HR) and their 95% confidence interval (95% CI) in men and women, Padjusted: P-value adjusted for multiple testing. 
Model 1: Adjusted for age, sex ethnicity, deprivation index and comorbidity. 
Model 2; Adjusted for model 1 plus smoking, alcohol consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical activity and sedentary behaviours. 
Model 3: Adjusted for model 2 plus waist circumference.  
  
Liver 222,621 110 1.03 (1.00; 1.06) 0.046 0.966 1.03 (1.00; 1.07) 0.029 0.638 1.03 (1.00; 1.06) 0.043 0.946 
Lung 222,571 592 1.00 (0.99; 1.02) 0.604 1.00 1.01 (0.99; 1.02) 0.279 1.00 1.01 (0.99; 1.02) 0.356 1.00 
Lymphatic 222,612 233 1.02 (1.00; 1.04) 0.117 1.00 1.02 (1.00; 1.04) 0.073 1.00 1.02 (1.00; 1.04) 0.114 1.00 
Melanoma 222,634 38 0.96 (0.91; 1.01) 0.091 1.00 0.96 (0.91; 1.01) 0.105 1.00 0.96 (0.91; 1.01) 0.114 1.00 
Multiple 
Myeloma 222,631 51 1.01 (0.97; 1.06) 0.560 
1.00 
1.02 (0.98; 1.07) 0.400 
1.00 
1.02 (0.97; 1.06) 0.479 
1.00 
Non-Hodgkin 222,629 97 1.01 (0.98; 1.04) 0.603 1.00 1.01 (0.98; 1.04) 0.495 1.00 1.01 (0.98; 1.04) 0.572 1.00 
Oesophagus 222,629 76 1.01 (0.97; 1.05) 0.650 1.00 1.01 (0.97; 1.05) 0.584 1.00 1.01 (0.98; 1.05) 0.535 1.00 
Oral 222,634 28 1.00 (0.94; 1.06) 0.959 1.00 1.01 (0.95; 1.07) 0.858 1.00 1.01 (0.95; 1.07) 0.832 1.00 
Ovary 222,622 246 1.01 (0.99; 1.03) 0.573 1.00 1.01 (0.99; 1.03) 0.458 1.00 1.01 (0.99; 1.03) 0.441 1.00 
Pancreas 222,610 256 1.01 (0.99; 1.03) 0.564 1.00 1.01 (0.99; 1.03) 0.542 1.00 1.00 (0.99; 1.03) 0.634 1.00 
Stomach 222,628 65 1.01 (0.97; 1.05) 0.544 1.00 1.02 (0.98; 1.06) 0.417 1.00 1.01 (0.97; 1.05) 0.529 1.00 
Thyroid 222,632 3 0.89 (0.75; 1.07) 0.218 1.00 0.89 (0.75; 1.06) 0.180 1.00 0.88 (0.74; 1.05) 0.152 1.00 
Uterine 222,630 104 1.01 (0.98; 1.04) 0.680 1.00 1.01 (0.98; 1.04) 0.500 1.00 1.00 (0.97; 1.04) 0.773 1.00 
Supplementary Table S4: Association height (per 5 cm) and breast, cervix, endometrium, ovary and uterine cancer incidence and mortality by menopausal status. 
 Overall  Postmenopausal  Premenopausal  P interaction 
Breast  
Total/event 221,445/4,283 131,976/2,744 55,743/883  
HR (95% CI) 1.01 (1.01; 1.02) 1.02 (1.01; 1.02) 1.02 (1.01; 1.02) 0.936 
Total/deaths 222,616/272 132,751/180 55,956/56  
HR (95% CI) 1.02 (1.00; 1.04) 1.02 (0.99; 1.04) 1.02 (0.99; 1.04) 0.509 
Cervix  
Total/event 222,608/50 132,745/34 55,952/13  
HR (95% CI) 0.98 (0.94; 1.02) 0.98 (0.93; 1.03) 0.98 (0.93; 1.03) 0.774 
Total/deaths 222,628/10 132,759/6 55,957/3  
HR (95% CI) 0.97 (0.88; 1.07) 0.97 (0.85; 1.10) 0.97 (0.85; 1.10) 0.621 
Endometrium  
Total/event 222,486/646 132,638/526 55,944/94  
HR (95% CI) 0.99 (0.98; 1.00) 0.99 (0.98; 1.01) 0.99 (0.98; 1.01) 0.150 
Total/deaths 222,628/69 132,758/62 0,001/1  
HR (95% CI) 1.00 (0.96; 1.04) 1.00 (0.96; 1.04) 1.00 (0.96; 1.04) 0.931 
Ovary  
Total/event 222,497/515 132,663/380 55,940/78  
HR (95% CI) 1.01 (0.99; 1.02) 1.00 (0.99; 1.02) 1.00 (0.99; 1.02) 0.953 
Total/deaths 222,617/246 132,749/197 55,956/21  
HR (95% CI) 1.01 (0.99; 1.03) 1.01 (0.98; 1.03) 1.01 (0.98; 1.03) 0.563 
Uterine  
Total/event 222,443/713 132,607/574 55,934/111  
HR (95% CI) 0.99 (0.98; 1.00) 0.99 (0.98; 1.01) 0.99 (0.98; 1.01) 0.249 
Total/deaths 222,625/104 132,756/89 55,957/9  
HR (95% CI) 1.00 (0.97; 1.04) 1.01 (0.97; 1.04) 1.01 (0.97; 1.04) 0.801 
Data is presented as hazard ratio and their 95% intervals in women 
Model: Adjusted for age, sex ethnicity, deprivation index, comorbidity, smoking, hormone replacement, alcohol consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical activity, sedentary behaviours and waist circumference. HR: hazard ratio. 
  
Supplementary Table S5: Association height (per 5 cm) and lung cancer incidence and mortality by smoking status. 
 Overall  No smokers  Ex-smokers Current smokers P interaction 
Lung Incidence  
Total/event 192,076/1,026 95,266/104 73,286/468 23,524/454  
Men 1.02 (1.01; 1.02) 1.01 (0.98; 1.04) 1.02 (1.00; 1.03) 1.02 (1.00; 1.03) 0.720 
Total/event 222,478/881 133,818/180 69,255/380 19,405/321  
Women 1.00 (0.99; 1.01) 1.01 (0.99; 1.03) 1.00 (0.99; 1.02) 1.00 (0.98; 1.02) 0.129 
Lung Mortality  
Total/deaths 192,194/790 95,283/68 73,353/368 23,558/354  
Men 1.01 (1.00; 1.02) 1.03 (0.99; 1.07) 1.01 (1.00; 1.03) 1.01 (1.00; 1.03) 0.870 
Total/deaths 222,571/592 133,843/90 69,292/270 19,436/232  
Women 1.01 (0.99; 1.02) 1.02 (0.99; 1.06) 1.00 (0.98; 1.02) 1.00 (0.98; 1.02) 0.247 
Data is presented as hazard ratio and their 95% intervals in men and women 
Model: Adjusted for age, sex ethnicity, deprivation index, comorbidity, alcohol consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical activity, sedentary behaviours and waist circumference. HR: Hazard ratio 
  
Supplementary Table S6: Association height (per 5 cm) and liver and stomach cancer incidence and mortality by alcohol risk.  
 Overall  No risk OH  Risk OH  P interaction 
Liver Incidence  
Total/event 192,253/220 25,139/49 167,114/171  
Men 0.99 (0.97; 1.01) 1.00 (0.96; 1.04) 0.98 (0.96; 1.01) 0.700 
Total/event 222,610/156 52,950/59 169,660/97  
Women 1.02 (1.00; 1.05) 1.03 (0.99; 1.07) 1.02 (0.98; 1.05) 0.525 
Liver mortality  
Total/deaths 192,272/155 25,141/31 167,131/124  
Men 1.00 (0.97; 1.02) 1.00 (0.95; 1.05) 0.99 (0.97; 1.02) 0.971 
Total/deaths 222,621/110 52,952/42 169,669/68  
Women 1.03 (1.00; 1.06) 1.04 (0.99; 1.09) 1.03 (0.99; 1.07) 0.553 
Stomach incidence  
Total/event 192,216/314 25,131/58 167,085/256  
Men 0.99 (0.97; 1.01) 0.99 (0.96; 1.03) 0.99 (0.97; 1.01) 0.849 
Total/event 222,611/120 52,948/40 169,663/80  
Women 1.01 (0.98; 1.04) 1.01 (0.96; 1.06) 1.01 (0.98; 1.05) 0.984 
Stomach mortality  
Total/deaths 192,270/131 25,142/33 167,128/98  
Men 1.01 (0.98; 1.04) 1.03 (0.98; 1.08) 1.00 (0.97; 1.03) 0.463 
Total/deaths 222,628/65 52,955/22 169,673/43  
Women 1.01 (0.97; 1.05) 1.02 (0.96; 1.09) 1.00 (0.96; 1.05) 0.600 
Data is presented as hazard ratio and their 95% intervals in men and women 
Model: Adjusted for age, sex ethnicity, deprivation index, comorbidity, alcohol consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical activity, sedentary behaviours and waist circumference. OH: alcohol: Alcohol risk unit > once a week.  
  
Supplementary Table S7: Association height (per 5 cm) and 24 cancer sites incidence by group of height ≥ or < 162 cm, for women, ≥ or < 176 cm for men. 






Total Event HR 95% CI P value 
 
Padjusted 
P interation Padj 
   Men    Women     
All-cause <176m, <162w 98,433 8,101 1.01 (1.00; 1.01) 0.003 0.114 0.731 1.00 102,882 6,550 1.01 (1.01; 1.02) <0.001 <0.001 0.242 1.00 
 ≥176m, ≥162w 90,261 6,738 1.01 (1.00; 1.01) 0.013 0.455   116,191 7,294 1.01 (1.00; 1.01) 0.024 1.00   
Bladder <176m, <162w 100,258 484 1.01 (0.99; 1.03) 0.594 1.00 0.643 1.00 104,516 140 0.99 (0.95; 1.03) 0.536 1.00 0.810 1.00 
 ≥176m, ≥162w 91,798 364 1.01 (0.99; 1.04) 0.407 1.00   118,045 138 0.98 (0.94; 1.02) 0.336 1.00   
Brain <176m, <162w 100,352 134 1.02 (0.98; 1.06) 0.314 1.00 0.647 1.00 104,539 89 1.02 (0.97; 1.08) 0.389 1.00 0.691 1.00 
 ≥176m, ≥162w 91,870 126 1.00 (0.96; 1.04) 0.962 1.00   118,056 82 1.00 (0.95; 1.06) 0.922 1.00   
Colorectal <176m, <162w 100,152 819 1.00 (0.99; 1.02) 0.675 1.00 0.133 1.00 104,431 576 1.00 (0.98; 1.02) 0.747 1.00 0.284 1.00 
 ≥176m, ≥162w 91,715 684 0.99 (0.97; 1.00) 0.133 1.00   117,937 566 1.02 (1.00; 1.04) 0.051 1.00   
Gallbladder <176m, <162w 100,379 19 0.98 (0.89; 1.08) 0.695 1.00 0.798 1.00 104,552 22 1.05 (0.95; 1.17) 0.344 1.00 0.838 1.00 
 ≥176m, ≥162w 91,903 4 1.01 (0.80; 1.28) 0.922 1.00   118,076 22 1.04 (0.94; 1.15) 0.442 1.00   
Kidney <176m, <162w 100,338 235 1.00 (0.98; 1.04) 0.746 1.00 0.210 1.00 104,534 121 1.01 (0.96; 1.05) 0.762 1.00 0.600 1.00 
 ≥176m, ≥162w 91,858 201 0.98 (0.94; 1.01) 0.228 1.00   118,049 113 0.99 (0.95; 1.04) 0.679 1.00   
Leukaemia <176m, <162w 100,351 173 1.04 (1.01; 1.08) 0.018 0.612 0.613 1.00 104,539 83 1.03 (0.97; 1.08) 0.342 1.00 0.854 1.00 
 ≥176m, ≥162w 91,876 177 1.03 (0.99; 1.06) 0.139 1.00   118,061 117 1.01 (0.97; 1.06) 0.554 1.00   
Liver <176m, <162w 100,355 136 0.97 (0.94; 1.00) 0.091 1.00 0.078 1.00 104,542 79 0.99 (0.94; 1.05) 0.784 1.00 0.030 0.660 
 ≥176m, ≥162w 91,898 84 1.02 (0.98; 1.08) 0.340 1.00   118,068 77 1.08 (1.03; 1.13) 0.002 0.09   
Lung <176m, <162w 100,259 599 1.03 (1.01; 1.05) 0.003 0.114 0.146 1.00 104,469 475 1.02 (1.00; 1.05) 0.030 1.00 0.019 0.437 
 ≥176m, ≥162w 91,817 427 1.01 (0.98; 1.03) 0.601 1.00   118,009 406 0.98 (0.96; 1.01) 0.173 1.00   
Lymphatic <176m, <162w 100,261 571 1.02 (1.00; 1.04) 0.045 1.00 0.100 1.00 104,480 367 1.03 (1.00; 1.06) 0.024 1.00 0.273 1.00 
 ≥176m, ≥162w 91,791 521 1.04 (1.02; 1.06) <0.001 <0.001   117,987 468 1.01 (0.99; 1.03) 0.525 1.00   
Melanoma <176m, <162w 100,329 249 1.02 (0.99; 1.05) 0.140 1.00 0.648 1.00 104,490 220 1.02 (0.99; 1.06) 0.165 1.00 0.550 1.00 
 ≥176m, ≥162w 91,842 307 1.01 (0.99; 1.04) 0.295 1.00   118,002 323 1.01 (0.99; 1.04) 0.350 1.00   
Multiple 








 ≥176m, ≥162w 91,882 102 1.04 (0.99; 1.08) 0.089 1.00   118,059 99 1.01 (0.97; 1.06) 0.562 1.00   
Non-Hodgkin <176m, <162w 100,319 284 1.03 (1.00; 1.05) 0.074 1.00 0.181 1.00 104,510 187 1.04 (1.00; 1.07) 0.055 1.00 0.183 1.00 
 ≥176m, ≥162w 91,846 240 1.05 (1.02; 1.08) <0.001 <0.001   118,025 251 1.00 (0.97; 1.03) 0.997 1.00   
Oesophagus <176m, <162w 100,317 235 0.96 (0.93; 0.99) 0.005 0.180 0.647 1.00 104,541 67 1.03 (0.97; 1.09) 0.314 1.00 0.128 1.00 
 ≥176m, ≥162w 91,873 173 0.96 (0.92; 1.00) 0.028 0.924   118,061 68 0.96 (0.91; 1.03) 0.256 1.00   
Oral <176m, <162w 100,339 173 1.01 (0.97; 1.04) 0.761 1.00 0.657 1.00 104,542 89 0.96 (0.92; 1.01) 0.140 1.00 0.061 1.00 
 ≥176m, ≥162w 91,876 138 1.00 (0.96; 1.04) 0.823 1.00   118,055 75 1.02 (0.97; 1.07) 0.431 1.00   
Pancreas <176m, <162w 100,352 197 1.01 (0.98; 1.04) 0.588 1.00 0.597 1.00 104,526 156 1.01 (0.98; 1.05) 0.471 1.00 0.454 1.00 
 ≥176m, ≥162w 91,877 167 1.03 (0.99; 1.06) 0.162 1.00   118,057 143 1.03 (0.99; 1.07) 0.146 1.00   
Stomach <176m, <162w 100,339 174 0.97 (0.94; 1.00) 0.056 1.00 0.784 1.00 104,542 57 0.98 (0.92; 1.04) 0.410 1.00 0.260 1.00 
 ≥176m, ≥162w 91,877 140 0.98 (0.94; 1.02) 0.386 1.00   118,069 63 1.03 (0.98; 1.09) 0.272 1.00   
Thyroid <176m, <162w 100,373 18 1.00 (0.90; 1.12) 0.928 1.00 0.644 1.00 104,536 43 0.97 (0.91; 1.04) 0.387 1.00 0.223 1.00 
 ≥176m, ≥162w 91,903 25 0.96 (0.87; 1.06) 0.402 1.00   118,062 70 1.02 (0.97; 1.08) 0.470 1.00   
Prostate 








Breast ≥176m, ≥162w 91,553 1,552 1.01 (0.99; 1.02) 0.293 1.00   117,435 2,399 1.01 (1.00; 1.02) 0.070 1.00   
Testis/Cervix <176m, <162w 100,378 19 1.08 (0.96; 1.22) 0.191 1.00 0.077 1.00 104,544 26 1.03 (0.93; 1.13) 0.584 1.00 0.120 1.00 
 ≥176m, ≥162w 91,897 37 0.96 (0.88; 1.04) 0.292 1.00   118,069 24 0.91 (0.81; 1.01) 0.089 1.00   
Endometrium <176m, <162w -- -- -- --  --  104,484 354 1.00 (0.98; 1.03) 0.918 1.00 0.718 1.00 
 ≥176m, ≥162w -- -- -- --  --  118,007 292 1.00 (0.97; 1.03) 0.926 1.00   
Ovary <176m, <162w -- -- -- --  --  104,500 251 1.01 (0.98; 1.04) 0.395 1.00 0.710 1.00 
 ≥176m, ≥162w -- -- -- --  --  118,002 264 1.00 (0.97; 1.03) 0.943 1.00   
Uterine <176m, <162w -- -- -- --  --  104,457 380 1.00 (0.97; 1.02) 0.845 1.00 0.796 1.00 
 ≥176m, ≥162w -- -- -- --  --  117,991 333 0.99 (0.97; 1.02) 0.679 1.00   
Data is presented as hazard ratio and their 95% intervals in women. Model: Adjusted for age, sex ethnicity, deprivation index, comorbidity, smoking, alcohol consumption, 
fruit & vegetable, processed meat intake, oily fish, sleep, physical activity, sedentary behaviours and waist circumference. HR: hazard ratio. No data available (--). Padj: P-




Supplementary Table S8: Association between height and cancer incidence and mortality by IGF-1 concentration levels in men  
  INCIDENCE   MORTALITY  




Total/Death HR 95% CI P value 
Padjusted 
All-cause Low 94,400 /7,364 1.01 (1.00; 1.01) <0.001 <0.001 96,001 /1,887 1.01 (1.00; 1.01) 0.132 1.00 
 High 94,294 /7,475 1.01 (1.00; 1.01) <0.001 <0.001 95,880 /2,099 1.01 (1.00; 1.01) 0.051 1.00 
Bladder Low 96,093 /410 1.01 (0.99; 1.02) 0.303 1.00 96,198 /74 1.00 (0.96; 1.03) 0.939 1.00 
 High 95,963 /438 1.00 (0.99; 1.01) 0.949 1.00 96,086 /65 1.02 (0.98; 1.05) 0.387 1.00 
Brain Low 96,161 /144 1.02 (0.99; 1.05) 0.127 1.00 96,180 /125 1.02 (0.99; 1.05) 0.162 1.00 
 High 96,061 /116 1.00 (0.97; 1.03) 0.961 1.00 96,074 /106 0.99 (0.96; 1.02) 0.531 1.00 
Colorectal Low 95,979 /746 1.01 (0.99; 1.02) 0.339 1.00 96,182 /214 0.99 (0.97; 1.01) 0.520 1.00 
 High 95,888 /757 0.99 (0.98; 1.00) 0.203 1.00 96,072 /203 1.01 (0.99; 1.03) 0.238 1.00 
Gallbladder Low 96,196 /8 0.92 (0.82; 1.02) 0.108 1.00 96,197 /5 0.96 (0.84; 1.10) 0.525 1.00 
 High 96,086 /15 0.96 (0.89; 1.04) 0.284 1.00 96,087 /9 0.90 (0.82; 0.99) 0.035 1.00 
Kidney Low 96,147 /229 1.01 (0.99; 1.03) 0.263 1.00 96,190 /81 1.01 (0.98; 1.05) 0.431 1.00 
 High 96,049 /207 0.99 (0.97; 1.01) 0.308 1.00 96,083 /72 0.98 (0.95; 1.01) 0.247 1.00 
Leukaemia Low 96,170 /164 1.02 (1.00; 1.04) 0.085 1.00 96,193 /74 1.00 (0.97; 1.04) 0.990 1.00 
 High 96,057 /186 1.04 (1.02; 1.06) <0.001 <0.001 96,082 /86 1.04 (1.01; 1.08) 0.011 0.429 
Liver Low 96,187 /48 0.98 (0.94; 1.02) 0.284 1.00 96,192 /34 0.97 (0.92; 1.02) 0.199 1.00 
 High 96,066 /172 1.00 (0.97; 1.02) 0.681 1.00 96,080 /121 1.01 (0.98; 1.04) 0.519 1.00 
Lung Low 96,100 /419 1.01 (1.00; 1.03) 0.056 1.00 96,147 /315 1.01 (0.99; 1.02) 0.385 1.00 
 High 95,976 /607 1.02 (1.00; 1.03) 0.006 0.204 96,047 /475 1.02 (1.00; 1.03) 0.013 0.494 
Lymphatic Low 96,093 /530 1.02 (1.00; 1.03) 0.008 0.264 96,183 /185 1.01 (0.99; 1.03) 0.522 1.00 
 High 95,959 /562 1.03 (1.01; 1.04) <0.001 <0.001 96,067 /195 1.03 (1.01; 1.05) 0.010 0.400 
Melanoma Low 96,141 /304 1.02 (1.00; 1.04) 0.020 0.640 96,198 /33 1.03 (0.98; 1.09) 0.260 1.00 
 High 96,030 /252 1.03 (1.01; 1.05) <0.001 <0.001 96,085 /31 1.00 (0.95; 1.05) 0.978 1.00 
Multiple 
Myeloma Low 96,172 /117 1.01 (0.98; 1.04) 0.620 
1.00 
96,194 /28 1.00 (0.94; 1.06) 0.895 
1.00 
 High 96,069 /111 1.01 (0.99; 1.04) 0.308 1.00 96,088 /26 1.06 (1.00; 1.12) 0.040 1.00 
Non-Hodgkin Low 96,147 /251 1.03 (1.01; 1.05) 0.003 0.105 96,192 /76 1.03 (0.99; 1.06) 0.104 1.00 
 High 96,018 /273 1.02 (1.00; 1.04) 0.051 1.00 96,079 /81 0.99 (0.96; 1.03) 0.680 1.00 
Oesophagus Low 96,148 /195 0.98 (0.96; 1.00) 0.049 1.00 96,187 /131 0.99 (0.96; 1.02) 0.429 1.00 
 High 96,042 /213 0.98 (0.96; 1.00) 0.086 1.00 96,076 /131 0.97 (0.94; 0.99) 0.014 0.518 
Oral Low 96,161 /121 1.01 (0.99; 1.04) 0.317 1.00 96,197 /28 1.02 (0.96; 1.08) 0.557 1.00 
 High 96,054 /190 0.99 (0.97; 1.02) 0.632 1.00 96,088 /45 1.01 (0.97; 1.06) 0.557 1.00 
Pancreas Low 96,169 /197 1.01 (0.99; 1.03) 0.248 1.00 96,176 /168 1.02 (0.99; 1.04) 0.171 1.00 
 High 96,060 /167 1.01 (0.99; 1.03) 0.340 1.00 96,070 /138 1.00 (0.98; 1.03) 0.924 1.00 
Prostate Low 95,798 /1,896 1.00 (0.99; 1.00) 0.572 1.00 96,188 /165 1.00 (0.97; 1.02) 0.851 1.00 
 High 95,731 /1,670 1.01 (1.00; 1.01) 0.052 1.00 96,085 /177 1.02 (1.00; 1.04) 0.087 1.00 
Stomach Low 96,164 /144 0.97 (0.95; 1.00) 0.049 1.00 96,189 /65 1.01 (0.97; 1.04) 0.781 1.00 
 High 96,052 /170 1.00 (0.98; 1.03) 0.724 1.00 96,081 /66 1.01 (0.98; 1.05) 0.511 1.00 
Testis Low 96,191 /27 1.04 (0.98; 1.10) 0.204 1.00 0,001 /1 1.00 (1.00; 1.00) 1.000 1.00 
 High 96,084 /29 1.03 (0.98; 1.09) 0.238 1.00 0,001 /1 1.00 (1.00; 1.00) 1.000 1.00 
Thyroid Low 96,190 /28 1.02 (0.97; 1.08) 0.440 1.00 96,198 /2 0.96 (0.77; 1.20) 0.733 1.00 
 High 96,086 /15 0.99 (0.91; 1.06) 0.716 1.00 96,090 /3 0.97 (0.82; 1.15) 0.741 1.00 
Data is presented as hazard ratio and their 95% intervals in men and women 
Model: Adjusted for age, sex ethnicity, deprivation index, comorbidity, smoking, alcohol consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical 
activity, sedentary behaviours and waist circumference.IGF-1: Insulin-like growth factor. HR: Hazard Ratio, CI: confidence interval. IGF-1: Low (Mean: 15.7, SD: 2.9), 
Middle (Mean: 21.1, SD: 1.9), High (Mean: 27.3, SD: 4.2). Padj: P-value adjusted for multiple testing 
  
Supplementary Table S9: Association between height and cancer incidence and mortality by IGF-1 concentration levels in women. 
  INCIDENCE MORTALITY 




Total/Death HR 95% CI P value 
Padjusted 
All-cause Low 94,563 /6,422 1.01 (1.01; 1.02) <0.001 <0.001 96,109 /1,352 1.01 (1.00; 1.02) 0.021 0.945 
 High 108,875 /6,819 1.01 (1.01; 1.01) <0.001 <0.001 110,518 /1,551 1.01 (1.00; 1.02) 0.035 1.00 
Bladder Low 96,206 /131 1.01 (0.98; 1.04) 0.632 1.00 96,237 /15 1.03 (0.95; 1.11) 0.529 1.00 
 High 110,590 /140 0.99 (0.97; 1.02) 0.636 1.00 110,628 /19 0.99 (0.92; 1.07) 0.852 1.00 
Brain Low 96,211 /91 1.02 (0.99; 1.06) 0.176 1.00 96,227 /79 1.01 (0.98; 1.05) 0.515 1.00 
 High 110,619 /74 0.97 (0.93; 1.00) 0.077 1.00 110,626 /62 0.98 (0.94; 1.02) 0.358 1.00 
Breast Low 95,682 /2,034 1.01 (1.01; 1.02) <0.001 <0.001 96,232 /129 1.02 (1.00; 1.05) 0.084 1.00 
 High 110,074 /1,957 1.01 (1.01; 1.02) <0.001 <0.001 110,625 /130 1.01 (0.98; 1.04) 0.553 1.00 
Cervix Low 96,229 /18 0.98 (0.91; 1.06) 0.676 1.00 96,232 /0 1.00 (1.00; 1.00) 1.000 1.00 
 High 110,621 /30 0.98 (0.92; 1.04) 0.434 1.00 110,630 /5 0.95 (0.83; 1.10) 0.501 1.00 
Colorectal Low 96,105 /554 1.00 (0.98; 1.01) 0.681 1.00 96,229 /142 1.02 (0.99; 1.05) 0.111 1.00 
 High 110,501 /540 1.01 (1.00; 1.03) 0.057 1.00 110,623 /139 1.00 (0.97; 1.03) 0.999 1.00 
Endometrium Low 96,173 /281 1.00 (0.98; 1.02) 0.849 1.00 96,237 /33 1.02 (0.96; 1.08) 0.486 1.00 
 High 110,552 /344 0.98 (0.96; 0.99) 0.009 0.342 110,630 /36 0.98 (0.93; 1.04) 0.546 1.00 
Gallbladder Low 96,236 /16 1.02 (0.94; 1.10) 0.635 1.00 96,237 /9 0.99 (0.89; 1.10) 0.854 1.00 
 High 110,626 /28 1.03 (0.97; 1.09) 0.340 1.00 110,631 /15 1.04 (0.96; 1.13) 0.366 1.00 
Kidney Low 96,218 /97 1.00 (0.97; 1.03) 0.881 1.00 96,235 /30 0.96 (0.91; 1.02) 0.179 1.00 
 High 110,599 /133 1.00 (0.97; 1.02) 0.779 1.00 110,626 /21 1.01 (0.94; 1.08) 0.804 1.00 
Leukaemia Low 96,219 /98 1.04 (1.01; 1.08) 0.013 0.481 96,231 /36 1.06 (1.00; 1.11) 0.047 1.00 
 High 110,615 /96 1.03 (0.99; 1.06) 0.124 1.00 110,626 /40 1.01 (0.96; 1.06) 0.634 1.00 
Liver Low 96,229 /56 1.01 (0.97; 1.05) 0.722 1.00 96,233 /38 1.02 (0.97; 1.08) 0.402 1.00 
 High 110,616 /96 1.03 (1.00; 1.07) 0.051 1.00 110,623 /69 1.04 (1.00; 1.08) 0.055 1.00 
Lung Low 96,165 /415 1.01 (0.99; 1.02) 0.355 1.00 96,202 /271 1.01 (0.99; 1.03) 0.467 1.00 
 High 110,548 /454 1.00 (0.98; 1.01) 0.973 1.00 110,603 /316 1.01 (0.99; 1.02) 0.582 1.00 
Lymphatic Low 96,154 /379 1.03 (1.02; 1.05) <0.001 <0.001 96,225 /105 1.04 (1.00; 1.07) 0.029 1.00 
 High 110,552 /432 1.02 (1.01; 1.04) 0.005 0.195 110,621 /124 1.00 (0.98; 1.03) 0.790 1.00 
Melanoma Low 96,171 /249 1.03 (1.01; 1.05) 0.004 0.160 96,237 /15 0.96 (0.89; 1.05) 0.375 1.00 
 High 110,566 /260 1.02 (1.00; 1.04) 0.039 1.00 110,631 /20 0.96 (0.90; 1.04) 0.310 1.00 
Multiple 
Myeloma Low 96,220 /92 1.02 (0.99; 1.06) 0.168 
1.00 
96,236 /26 1.00 (0.94; 1.06) 0.918 
1.00 
 High 110,617 /88 1.02 (0.98; 1.05) 0.334 1.00 110,629 /24 1.04 (0.98; 1.11) 0.211 1.00 
Non-Hodgkin Low 96,191 /188 1.04 (1.01; 1.06) 0.002 0.082 96,235 /42 1.06 (1.01; 1.11) 0.029 1.00 
 High 110,581 /239 1.02 (1.00; 1.05) 0.022 0.748 110,628 /55 0.98 (0.94; 1.02) 0.278 1.00 
Oesophagus Low 96,222 /64 0.99 (0.95; 1.03) 0.522 1.00 96,235 /38 0.99 (0.94; 1.04) 0.752 1.00 
 High 110,616 /68 1.04 (1.00; 1.08) 0.057 1.00 110,629 /38 1.03 (0.98; 1.09) 0.236 1.00 
Oral Low 96,221 /67 0.98 (0.95; 1.02) 0.448 1.00 96,237 /7 1.03 (0.91; 1.16) 0.686 1.00 
 High 110,613 /92 0.98 (0.95; 1.02) 0.329 1.00 110,631 /20 1.00 (0.93; 1.07) 0.965 1.00 
Ovary Low 96,185 /222 1.03 (1.00; 1.05) 0.018 0.630 96,231 /103 1.02 (0.99; 1.06) 0.157 1.00 
 High 110,554 /273 0.99 (0.97; 1.01) 0.460 1.00 110,625 /139 1.00 (0.97; 1.03) 0.886 1.00 
Pancreas Low 96,215 /140 0.99 (0.97; 1.02) 0.600 1.00 96,225 /123 0.99 (0.97; 1.02) 0.733 1.00 
 High 110,603 /154 1.03 (1.00; 1.06) 0.031 1.00 110,619 /129 1.02 (0.99; 1.04) 0.291 1.00 
Stomach Low 96,224 /55 0.99 (0.95; 1.04) 0.707 1.00 96,234 /27 1.02 (0.96; 1.08) 0.554 1.00 
 High 110,622 /62 1.03 (0.99; 1.07) 0.177 1.00 110,628 /37 1.01 (0.96; 1.06) 0.735 1.00 
Thyroid Low 96,215 /52 1.02 (0.98; 1.07) 0.276 1.00 96,236 /0 NA.    
 High 110,617 /52 1.03 (0.99; 1.08) 0.172 1.00 110,630 /3 0.87 (0.72; 1.06) 0.165 1.00 
Uterine Low 96,156 /302 1.00 (0.98; 1.02) 0.919 1.00 96,237 /51 1.03 (0.98; 1.08) 0.208 1.00 
 High 110,529 /388 0.98 (0.96; 1.00) 0.014 0.504 110,628 /52 0.98 (0.94; 1.03) 0.461 1.00 
Data is presented as hazard ratio and their 95% intervals in men and women 
Model: Adjusted for age, sex ethnicity, deprivation index, comorbidity, smoking, alcohol consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical 
activity, sedentary behaviours and waist circumference.IGF-1: Insulin-like growth factor. HR: Hazard Ratio, CI: confidence interval. IGF-1: Low (Mean: 15.7, SD: 2.9), 





Supplementary Figure S4. Ratio of HR of low to high IGF-1 level for the association of height with mortality of 24 
cancer sites men and women. 
Data presented as ratio of hazard ratio (interaction term of IGF-1 level and height) and their 95% CI per 5-cm 
increment in height. Models were adjusted for age, ethnicity, deprivation index, comorbidity, smoking, alcohol 
consumption, fruit & vegetable, processed meat intake, oily fish, sleep, physical activity, sedentary behaviours and 
waist circumference. Padj: P-value adjusted for multiple testing 
 
 
